Global Brucella Abortus Vaccine Market Size By Type (DNA Vaccines, Subunit Vaccines), By Application (Cattles, Sheep), By Region, And Segment Forecasts, 2023 to 2032

The Global Brucella Abortus Vaccine Market was valued at USD 248 million in 2023 and is projected to surpass USD 426 million by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. Brucella abortus vaccines play a critical role in veterinary medicine by controlling brucellosis in cattle and preventing its zoonotic transmission to humans. The rising prevalence of bovine brucellosis, growing awareness of zoonotic diseases, and expanding livestock populations are driving market growth globally.

Drivers:

Increasing Livestock Population and Zoonotic Disease Risk:

The growing demand for dairy and meat products is increasing cattle farming activities worldwide. Consequently, the risk of brucellosis outbreaks rises, fueling demand for Brucella abortus vaccines to protect animal health and prevent human transmission.

Government-Led Vaccination Programs:

Various governments and veterinary agencies have initiated brucellosis control programs, especially in endemic regions. Subsidized vaccine distribution and mass immunization campaigns are accelerating vaccine adoption globally.

Veterinary Healthcare Advancements:

Technological developments in veterinary biologics, coupled with improved cold chain logistics and distribution channels, are enhancing the accessibility and effectiveness of Brucella abortus vaccines.

Restraints:

Vaccine Handling Complexity:

Live attenuated vaccines, like the RB51 strain, require strict storage conditions and careful administration, posing challenges in rural or under-resourced regions.

Limited Awareness in Low-Income Regions:

Inadequate veterinary infrastructure and low awareness of brucellosis impact vaccine penetration, especially in sub-Saharan Africa and parts of Southeast Asia.

Opportunity:

Expansion into Emerging Markets:

Regions like Latin America, Africa, and Southeast Asia are expected to provide robust growth opportunities due to rising livestock numbers and strengthening veterinary services.

Development of Novel Vaccine Strains:

Ongoing R&D into safer, more effective vaccines—including inactivated or recombinant variants—can overcome current vaccine limitations and open new market segments.

Market by System Type Insights:

The Live Attenuated Vaccines segment held the dominant market share in 2023. These vaccines are widely used due to their high efficacy and long-lasting immunity. However, the Inactivated Vaccines segment is anticipated to witness the fastest growth during the forecast period, driven by safety advantages and regulatory approvals for use in both pregnant animals and disease-free regions.

Market by End-use Insights:

In 2023, the Veterinary Clinics and Hospitals segment emerged as the leading end-use category, accounting for over 45% of global revenue. This is due to their central role in disease diagnostics, vaccination, and animal health services. The Government Veterinary Agencies segment is projected to grow rapidly, supported by large-scale public health immunization programs targeting brucellosis eradication.

Market by Regional Insights:

North America dominated the global Brucella abortus vaccine market in 2023, thanks to strong regulatory frameworks, high veterinary awareness, and the presence of established vaccine manufacturers. Meanwhile, Asia-Pacific is expected to register the highest CAGR during the forecast period due to increasing livestock density and greater focus on disease control measures in countries like India, China, and Indonesia.

Competitive Scenario:

Key players in the market include Zoetis Inc., Merck Animal Health, Indian Immunologicals Ltd., Colorado Serum Company, Boehringer Ingelheim, Vaxxinova, and Ceva Santé Animale. These companies are engaged in product innovation, international expansion, and collaborations with public health agencies to solidify their market presence.

Scope of Work – Global Brucella Abortus Vaccine Market

Key Market Developments:

2023: Indian Immunologicals Ltd. launched an enhanced version of the Brucella abortus S19 vaccine with improved thermostability, reducing dependency on cold chain logistics.

2024: Zoetis announced a partnership with Latin American governments to distribute RB51 vaccines under rural livestock health initiatives.

2025: Vaxxinova received approval for a new recombinant Brucella vaccine targeted at safer administration during pregnancy and in disease-free herds.

FAQs:

1) What is the current market size of the Global Brucella Abortus Vaccine Market?

The market was valued at USD 248 million in 2023.

2) What is the major growth driver of the Global Brucella Abortus Vaccine Market?

The primary growth driver is the increasing prevalence of bovine brucellosis and government-supported mass vaccination programs.

3) Which is the largest region during the forecast period in the Global Brucella Abortus Vaccine Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Brucella Abortus Vaccine Market?

The Live Attenuated Vaccine segment dominated the market in 2023.

5) Who are the key market players in the Global Brucella Abortus Vaccine Market?

Major players include Zoetis Inc., Merck Animal Health, Indian Immunologicals Ltd., Boehringer Ingelheim, and Ceva Santé Animale.